|
|
Post by lojothehus on Mar 3, 2017 10:57:24 GMT -5
M & M, it's time to fight back. Please put some fear into these shorts! Announce something, even if it's what you guys are doing in the office today. Announce what you had for breakfast and what you will be doing this weekend. Announce something!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 3, 2017 11:02:19 GMT -5
M & M, it's time to fight back. Please put some fear into these shorts! Announce something, even if it's what you guys are doing in the office today. Announce what you had for breakfast and what you will be doing this weekend. Announce something! how about some sales rather than fear? |
|
|
|
Post by lojothehus on Mar 3, 2017 11:08:43 GMT -5
M & M, it's time to fight back. Please put some fear into these shorts! Announce something, even if it's what you guys are doing in the office today. Announce what you had for breakfast and what you will be doing this weekend. Announce something! how about some sales rather than fear? Fear will allay the shorts from pounding us, and advertisements and hype will boost the sales. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 3, 2017 11:12:02 GMT -5
how about some sales rather than fear? Fear will allay the shorts from pounding us, and advertisements and hype will boost the sales. ok. We all know that. the tape has been played over and over. |
|
|
|
Post by lojothehus on Mar 3, 2017 11:47:58 GMT -5
Fear will allay the shorts from pounding us, and advertisements and hype will boost the sales. ok. We all know that. the tape has been played over and over. Well wouldn't you agree that it is time to do something about it? That's the gist of the post. |
|
|
|
Post by derek2 on Mar 3, 2017 12:15:30 GMT -5
ok. We all know that. the tape has been played over and over. Well wouldn't you agree that it is time to do something about it? That's the gist of the post. Short sellers aren't what's killing the share price. Poor management and poor sales are. 1/12/2016 Short Interest 130,253,946 Share price: $0.96 2/15/2017 Short Interest 101,613,853 Share Price: $0.53 30M fewer short shares = 30M shares purchased to cover, yet the share price gets cut in half. Look to management, not to a scapegoat. if anything, short sellers supported the share price by taking profits. In the meantime, MNKD issued millions of warrants that short sellers use to protect their position. While we're at it, although I have never shorted the stock of any company (my registered investment account does not allow it, and I'm just as happy about that), the short investment thesis: IS NOT: "I hate diabetics so I'll bankrupt a biotech company" (Shorting doesn't bankrupt companies. Running out of money does) It IS: "I think the share price will be lower in the future" OR "I think shorting this company will be a hedge to my investment in another company" That said, I just looked at the SP. $1.87. Makes me want to cry. A pile-on of selling (shorting or longs lightening positions) could indeed take this under $1.00 in the next 10 days. The BOD should be ashamed of themselves for not selecting the 10:1. It would have given a much larger margin of safety. |
|
|
|
Post by lojothehus on Mar 3, 2017 12:32:30 GMT -5
Well wouldn't you agree that it is time to do something about it? That's the gist of the post. Short sellers aren't what's killing the share price. Poor management and poor sales are. 1/12/2016 Short Interest 130,253,946 Share price: $0.96 2/15/2017 Short Interest 101,613,853 Share Price: $0.53 30M fewer short shares = 30M shares purchased to cover, yet the share price gets cut in half. Look to management, not to a scapegoat. if anything, short sellers supported the share price by taking profits. In the meantime, MNKD issued millions of warrants that short sellers use to protect their position. While we're at it, although I have never shorted the stock of any company (my registered investment account does not allow it, and I'm just as happy about that), the short investment thesis: IS NOT: "I hate diabetics so I'll bankrupt a biotech company" (Shorting doesn't bankrupt companies. Running out of money does) It IS: "I think the share price will be lower in the future" OR "I think shorting this company will be a hedge to my investment in another company" That said, I just looked at the SP. $1.87. Makes me want to cry. A pile-on of selling (shorting or longs lightening positions) could indeed take this under $1.00 in the next 10 days. The BOD should be ashamed of themselves for not selecting the 10:1. It would have given a much larger margin of safety. I agree, but of course I subscribe to the age old adage that if you are going to sale something that you want people to buy, someone has to talk about it. When people talk about it, people buy it and "boom" there goes your sales. You run out of money when you hire and send a bunch of sales reps to go to doctor's office and talk about a drug that no ones heard of. ADVERTISE it on television, people will go to their doctors and inquire and request it, and the sales representatives will be able to do their jobs. I am not an expert at this, but I think I'm on to something here. |
|
|
|
Post by agedhippie on Mar 3, 2017 14:37:37 GMT -5
While we're at it, although I have never shorted the stock of any company (my registered investment account does not allow it, and I'm just as happy about that), the short investment thesis: IS NOT: "I hate diabetics so I'll bankrupt a biotech company" (Shorting doesn't bankrupt companies. Running out of money does) It IS: "I think the share price will be lower in the future" OR "I think shorting this company will be a hedge to my investment in another company" Case in point. Look at Novo Nordisk over the last year - horrible performance, down 39% if you had simply bought their stock. Suppose you had thought they were going to do well but you wanted a hedge - MNKD is under-performing so select them as the short side. After 1 year you lost 39% on the long side, and made 64% on the short side. Overall you are up 25% rather than down 39%. |
|
|
|
Post by careful2invest on Mar 3, 2017 17:36:20 GMT -5
Short sellers aren't what's killing the share price. Poor management and poor sales are. 1/12/2016 Short Interest 130,253,946 Share price: $0.96 2/15/2017 Short Interest 101,613,853 Share Price: $0.53 30M fewer short shares = 30M shares purchased to cover, yet the share price gets cut in half. Look to management, not to a scapegoat. if anything, short sellers supported the share price by taking profits. In the meantime, MNKD issued millions of warrants that short sellers use to protect their position. While we're at it, although I have never shorted the stock of any company (my registered investment account does not allow it, and I'm just as happy about that), the short investment thesis: IS NOT: "I hate diabetics so I'll bankrupt a biotech company" (Shorting doesn't bankrupt companies. Running out of money does) It IS: "I think the share price will be lower in the future" OR "I think shorting this company will be a hedge to my investment in another company" That said, I just looked at the SP. $1.87. Makes me want to cry. A pile-on of selling (shorting or longs lightening positions) could indeed take this under $1.00 in the next 10 days. The BOD should be ashamed of themselves for not selecting the 10:1. It would have given a much larger margin of safety. I agree, but of course I subscribe to the age old adage that if you are going to sale something that you want people to buy, someone has to talk about it. When people talk about it, people buy it and "boom" there goes your sales. You run out of money when you hire and send a bunch of sales reps to go to doctor's office and talk about a drug that no ones heard of. ADVERTISE it on television, people will go to their doctors and inquire and request it, and the sales representatives will be able to do their jobs. I am not an expert at this, but I think I'm on to something here. I'd say that you are definitely onto something, to put it mildly. It is such a blatantly obvious concept to make your potential customer aware of the goods that you want to market, (that is only if you intend to sell as much of your product as possible) that it almost seems intentional that MNKD management wants to bury this company as much as BP wants it gone! A reverse split, with no announcement of something positive to reduce or eliminate further dillution?? What are they (MNKD) thinking? With each decision, there is another missed opportunity, another blunder. Seven plus years of disappointment. I have witnessed it even prior to FDA approval! Sad thing is, it's not even worth it to sell the shares that I have. Unfortunately, I just have to ride it out. Hopefully they can turn it around! It just does not make sense! |
|
|
|
Post by dreamboatcruise on Mar 3, 2017 18:03:54 GMT -5
I agree, but of course I subscribe to the age old adage that if you are going to sale something that you want people to buy, someone has to talk about it. When people talk about it, people buy it and "boom" there goes your sales. You run out of money when you hire and send a bunch of sales reps to go to doctor's office and talk about a drug that no ones heard of. ADVERTISE it on television, people will go to their doctors and inquire and request it, and the sales representatives will be able to do their jobs. I am not an expert at this, but I think I'm on to something here. I'd say that you are definitely onto something, to put it mildly. It is such a blatantly obvious concept to make your potential customer aware of the goods that you want to market, (that is only if you intend to sell as much of your product as possible) that it almost seems intentional that MNKD management wants to bury this company as much as BP wants it gone! A reverse split, with no announcement of something positive to reduce or eliminate further dillution??
What are they (MNKD) thinking?With each decision, there is another missed opportunity, another blunder. Seven plus years of disappointment. I have witnessed it even prior to FDA approval! Sad thing is, it's not even worth it to sell the shares that I have. Unfortunately, I just have to ride it out. Hopefully they can turn it around! It just does not make sense! That portion is pretty easy to explain. They were thinking that NASDAQ forced them to RS and that they have nothing positive to announce... nothing beyond the rather modestly positive things they tried to highlight. If there were something significantly positive to announce they could have done it and likely avoided the need to RS. The something simply doesn't exist. "Hopefully" that begins to change. |
|
|
|
Post by matt on Mar 4, 2017 14:43:11 GMT -5
Shorting doesn't bankrupt companies. Running out of money does This is the ultimate issue. We know what the gross sales of Afrezza are in the market, and we know how much the company spends per month to support those sales. Heading into Q4 there were only a few pots of money hiding out there, a Sanofi settlement and sale of the Valencia facility, and those have now been monetized. Anybody with a spreadsheet can calculate the month when the money finally runs out and anybody who knows anything about Deerfield Partners knows they are not bashful about seizing their collateral upon a default. It comes down to a long bet that MNKD can find enough fresh capital to support Launch 3.0 on terms that are not horribly dilutive, or make some deals that come with big up-front payments, or some combination of the two, before the money runs out sometime around July. The short thesis is that any capital raise will be so punitively expensive that it will drive the share price down another 30-40%, there will be no material deals, or that the company will have to file for bankruptcy just to obtain the automatic stay that will prevent Deerfield from foreclosing on the Danbury plant. You may hate the shorts as much as you love the product, but given the condition of the balance sheet and track record of management on deal making, their thesis is not crazy. July is only four months away. |
|
|
|
Post by mnholdem on Mar 4, 2017 17:05:23 GMT -5
One of the more innovative solutions recently used by biotech startups is to secure royalty-based financing, where MannKind would need to fork over a percentage of future profits. However, if the company doesn't start some serious sales growth over the few months, even that financing option may be out of reach.
|
|
|
|
Post by peppy on Mar 4, 2017 17:19:19 GMT -5
Shorting doesn't bankrupt companies. Running out of money does This is the ultimate issue. We know what the gross sales of Afrezza are in the market, and we know how much the company spends per month to support those sales. Heading into Q4 there were only a few pots of money hiding out there, a Sanofi settlement and sale of the Valencia facility, and those have now been monetized. Anybody with a spreadsheet can calculate the month when the money finally runs out and anybody who knows anything about Deerfield Partners knows they are not bashful about seizing their collateral upon a default. It comes down to a long bet that MNKD can find enough fresh capital to support Launch 3.0 on terms that are not horribly dilutive, or make some deals that come with big up-front payments, or some combination of the two, before the money runs out sometime around July. The short thesis is that any capital raise will be so punitively expensive that it will drive the share price down another 30-40%, there will be no material deals, or that the company will have to file for bankruptcy just to obtain the automatic stay that will prevent Deerfield from foreclosing on the Danbury plant. You may hate the shorts as much as you love the product, but given the condition of the balance sheet and track record of management on deal making, their thesis is not crazy. July is only four months away. Motives are interesting. Undoubtedly, you are here to help. |
|
|
|
Post by agedhippie on Mar 4, 2017 17:20:55 GMT -5
One of the more innovative solutions recently used by biotech startups is to secure royalty-based financing, where MannKind would need to fork over a percentage of future profits. However, if the company doesn't start some serious sales growth over the few months, even that financing option may be out of reach. They already did that with Deerfield. There are sales milestones in those agreements. We are nowhere near triggering them though  |
|
|
|
Post by sportsrancho on Mar 5, 2017 21:53:09 GMT -5
I'm fighting back the only way I know how.
All this bitching, it is what is is. And sometimes good for the soul. I did a lot of bitching about those other reps. But we are on a new path. The only thing we can do is put one foot in front of the other. Tell someone about Afrezza when ever we get the chance. Support Matt and Mike and our new sales team! What do we have to lose? It's your money!
|
|
